Pursuing new indications and fortifying existing IP

The next drug planned for our pipeline targets inflammatory bowel disease (“IBD”), an attractive market long in need of safer, more effective therapies.

Inflammatory Bowel Disease

Intended to address the need for a safe and more effective drug for mild-to-moderate IBD, this drug is aimed at delaying or avoiding the use of expensive, adverse effect-prone immunomodulators, corticosteroids, and biologics.

Currently undergoing screening, the candidate molecules are modeled on the architecture of ATB-429, a hydrogen sulfide-releasing IBD drug molecule with extensive and promising animal data but diminishing patent life. Once the final candidate is selected, Antibe plans to initiate IND-enabling studies.

Comprising treatments for Crohn’s disease and ulcerative colitis, the IBD market is expected to nearly double between 2019 and 2029 from $13 billion to $25 billion.1

New Chemistry Initiatives

In parallel with the development of pipeline drugs and IBD program, we are leveraging our hydrogen sulfide platform through a cost-effective, early-stage research and development program. In 2021, we entered into a strategic collaboration with Dalriada Drug Discovery to accelerate the identification of new drug candidates and to fortify the IP position of our current pipeline drugs, potentially extending their market protection into the 2040s.

……………………………………
1. GlobalData (2020).
2. Visiongain: Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029.

Attention

This is an external link. Click “OK” to continue.

CANCEL OK